To identify immunologically important domains on filamentous hemagglutinin (FHA), a Bordetella pertussis protein included in new acellular pertussis vaccines (ACPVs), a series of monoclonal antibodies, sera from infants vaccinated with ACPVs or whole cell pertussis vaccine (WCPV), and sera from patients with pertussis were analyzed by immunoblots containing FHA fragments and recombinant FHA proteins. Immunodominant domains located at the COOH-terminus of FHA (type I domain) and near the NH 2 -terminus (type II domain) were defined by the reactivity with monoclonal antibodies. The sera from patients with pertussis and sera from infants vaccinated with WCPV or with 6 different investigational ACPVs specifically recognized well-defined regions within the type I and type II domains. Identification of these prominent immunologic epitopes on FHA should be useful for the construction of more well-defined pertussis vaccines and for the interpretation of human serologic responses, which may correlate with efficacy of pertussis vaccines.
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Filamentous hemagglutinin (FHA) is a unique prokaryotic FHA. We have also examined sera produced in humans following disease or vaccination with whole cell pertussis vaccine protein that promotes the interaction of the human pathogen Bordetella pertussis with host cells [1] . FHA is an extracellu-(WCPV) or ACPVs for their reactivity with specific FHA domains. Antibody domains have been defined using fragments lar protein that can be identified on the surface of the bacterium and in the medium of cultured B. pertussis [2] . It has of FHA, fusion proteins, and synthetic peptides, and to our knowledge, we describe for the first time the characterization been shown that FHA can bind to the surface of B. pertussis [3, 4] , other bacteria [5] , and eukaryotic cells [1, 4, 6, 7] .
of two major immunodominant regions within FHA. These studies should provide the basis for further analysis of the FHA is analogous to eukaryotic proteins that mediate cellcell and cell-matrix interactions in that it contains the peptide serologic response to specific regions of FHA following disease and vaccination, which may correlate with protection against sequence RGD, which binds to integrins [7] , it binds to sulfated sugars such as heparin [8, 9] , and it has lectin-like B. pertussis infection. properties [10] . FHA also elicits protective antibodies in animals challenged with B. pertussis [11 -13] and is a compoMaterials and Methods nent in many of the new acellular pertussis vaccines (ACPVs) [14 -16] .
Production of recombinant proteins. Escherichia coli TB1
FHA is a very large prokaryotic protein of 220 kDa, and (New England BioLabs, Beverly, MA) were grown in Luria-Bertani medium [17] , and E. coli TB1 containing recombinant pMALwhile its protective potential has clearly been demonstrated, c derivatives were grown in Luria-Bertani medium containing 100 its immunogenic regions have not yet been investigated in mg/mL of ampicillin. Recombinant FHA fragments used in this detail. In this report, we have examined the immune response study are described in table 1. Fusion proteins encoded by to FHA, using a series of monoclonal antibodies (MAbs) propMAL80, pMAL83, pMAL85, or pMAL2 were produced in duced in mice immunized with intact B. pertussis or purified E. coli TB1, using the pMAL-c expression system (New England BioLabs) and have been described elsewhere [19] . The FHA recombinant fragments GR7 and GR10 were produced in E. coli previously [18] . For inhibition assays, the MAbs were partially Epitope scanning. The epitopes of certain anti-FHA MAbs were determined by use of the Geysen Pin Technology system purified by precipitation in 50% ammonium sulfate followed by dialysis against Dulbecco's PBS (DPBS).
(Collaborative Research Biochemicals, Wilmington, DE) [25] . In total, 812 overlapping peptides, 15-amino acid (aa) residues long, Convalescent sera from patients with pertussis, sera from infants vaccinated with WCPV, and sera from infants vaccinated with were synthesized beginning at the NH 2 -terminus of FHA, with synthesis initiated at every fourth aa residue and continued over ACPV were supplied by the Laboratory of Pertussis, CBER, through the National Institutes of Allergy and Infectious Diseases the entire length of the FHA sequence. Synthesis of the peptides was accomplished by repetitive cycling of FMOC-deprotection, (NIAID), National Institutes of Health. The ACPVs used in this study were from phase II clinical trials sponsored by NIAID; dewashing, and coupling at the rate of addition of one aa per day. MAb reactivity was assayed by ELISA, using peptides embedded tails of the composition of the vaccines and the immunization schedule have been described by Edwards et al. [22] .
on the pins in microtiter plates and detected by use of peroxidaseconjugated goat anti-mouse immunoglobulin and the ABTS sub-SDS-PAGE and immunoblots. Purified FHA (a gift from SmithKline Beecham, Rixensart, Belgium), FHA fragments Fha44 strate. Blocks containing the pins with peptides were washed and utilized for more than one MAb screening. and Fha412 [20, 23] , or whole cell extracts of E. coli expressing the recombinant FHA fragments were resolved by 4%-20% SDS-PAGE according to the method of Laemmli [24] . The proteins were electroblotted onto membrane (Imobilon; Millipore Products,
Results
Bedford, MA) and incubated in 0.1% BRIJ 35 solution (Sigma, St.
Identification of immunodominant FHA domains by MAbs.
Louis) in DPBS for at least 1 h prior to incubation with hybridoma It has been previously shown that FHA protein undergoes sponsupernatants containing anti-FHA MAb for 2 h at room temperature. After being washed, the filters were incubated with alkaline taneous fragmentation, which occurs at the protease-sensitive phosphatase-conjugated goat anti-mouse antibody (Kirkegaard & arginine-rich site [18, 26, 27] , resulting in an NH 2 -terminal Perry, Gaithersburg, MD) for 2 h at room temperature. Nitrotetra-98-kDa polypeptide and a 150-kDa fragment containing the zolium plus 5-bromo-4-chloro-3-indolyl phosphate p-toluidine COOH-terminus of the mature protein (figure 1). Immunoblots the antibody-containing supernatants reacted with the 220-and
The blots were then incubated overnight at 4ЊC and probed using 98-kDa band but not with the 150-kDa fragment and are desiggoat anti-human antibody conjugated with alkaline peroxidase at a 1:500 dilution for 2 h, and blots were developed as described nated type II MAbs (table 2).
above.
To further define the regions of FHA recognized by these Hemagglutination assays. FHA-mediated hemagglutination antibodies, several recombinant FHA fragments produced by assays were done as previously described [19] in plates (V-well use of the pMAL-c or the pUC expression systems in E. coli (table 2 ). An example of a type IA antibody 100 mg/mL) of the partially purified MAbs in 50-mL aliquots were added to the assay. Amino-acid residues corresponding to first and last amino acids of various recombinant proteins and FHA fragments are designated by nos. according to numerical scheme proposed by Delisse-Gathoye et al. [18] .
and GR7 is shown in figure 2A , panel II. Since, with the 1655 and 2012, as illustrated in figure 1 . Pepscan analysis using the type IA antibodies 2/1:9F, 2/2:5D, and 5/1:4C suggests exception of weak binding of 12.5D1 to Mal83, the type IA antibodies generally do not recognize Mal83 or GR10, the that the epitope for these antibodies is within the sequence RGHTLESAEGRKIFG occurring at aa 2001 -2015 located major binding region for these antibodies must lie within the COOH-terminal region of mature FHA, between aa residues within Mal85. The remaining four type I antibodies reacted with the fusion X3C and X3E, reacted with Mal80, Mal83, and GR7 and are designated type IIB (table 2) . They also reacted strongly with proteins GR10, Mal85, and GR7 and are designated type IB. Figure 2A (panel III) shows the type IB antibody 12.6F8 bindthe B. pertussis -produced FHA fragments Fha44 and Fha412. Two antibodies, 12.1F9 and 12.2B11, reacted with Mal83 and ing to the 220-and 150-kDa fragments of FHA and to the fusion proteins Mal85, GR7, and GR10. These results indicate GR7 but not with Mal80 or any of the B. pertussis -produced FHA fragments; they are designated type IIC. Figure 2B illusthat the binding region for the type IB antibodies must lie near the COOH-terminus of FHA as determined by reactivity with trates the immunoblot results obtained when FHA and recombinant proteins were probed with the type IIB antibody, X3C, or GR10, a fusion protein that contains the fragment of FHA that starts at aa 2013 and extends beyond the end of the mature the type IIC antibody, 12.1F9. Although Mal80 and Mal83 do not overlap, they do contain protein. The four type IB antibodies were used in pepscan analysis, but no specific linear sequence on the peptides was similar repeat sequences, as noted by Delisse-Gathoye et al. [18] . These repeats, called the B repeats [1] , may serve as recognized.
Two of the type IA antibodies, 2/1:8F and 3C, weakly recogantibody-binding sites for type IIB antibodies. This was confirmed by pepscan analysis using antibodies X3C and X3E. nized Mal80 in addition to their strong recognition of Mal85 and GR7. These two antibodies were also the only antibodies
The most reactive pins corresponded to an aa sequence occurring within the B repeat sequence and found twice in Mal80, designated as type I that were reactive with the NH 2 -terminal FHA fragment Fha44 produced by B. pertussis. The reason for once in Mal83, and once in GR7. The consensus aa sequence for the type IIB antibody -binding domain determined by pepthis weak binding is not clear, but most likely is related to the presence of degenerated repeats throughout the FHA molecule, scan and sequence analyses is VsGrDAVRvd (capital letters denote the strictly conserved residues; small letters denote the as discussed below [28] . This may also be the reason why 12.5D1 weakly reacts with Mal83.
variable residues), and it is located within domain IIB (figure 1 of an immunoblot using sera from a convalescent patient is shown in figure 2C , panel I. several of the type I antibodies were the most inhibitory (table  2) . However, not all of the type I MAbs blocked hemagglutinaImmune response to FHA following vaccination with WCPV. Five serum samples obtained before and after vaccination from tion, and a weak inhibition was also observed using the type IIA antibodies.
children who received three doses of WCPV were also analyzed using immunoblots (table 3) . In all cases, there was an increase Immune response to FHA following pertussis disease. Immunoblot analyses using FHA and FHA fusion proteins were done in anti-FHA antibodies as measured by an FHA-specific ELISA. All prevaccination sera were negative by immunoblot using human sera to determine whether the human immune response to FHA following disease or vaccination with either analysis. All of the postvaccination sera showed reactivity with the 220-and 150-kDa FHA bands and with fusion protein WCPV or FHA-containing ACPVs results in antibodies reactive with the domains defined by the MAbs. HRP3 is a pooled Mal85, indicating that they contain anti-FHA antibodies that recognize the type I region of FHA. Two of the sera (418 and human reference serum obtained from patients recovering from pertussis, and it contains significant anti-FHA titers. B262 is 433) also recognized the 98-kDa fragment of FHA and Mal83, suggesting that these sera contain anti-FHA antibodies that a human serum sample with a low FHA titer as determined by ELISA and was used as a negative control (table 3) . Anti-sera recognize the type II domain as well as the type I region of FHA. from HRP3 contained anti-FHA antibodies that exclusively recognized the type I domain by immunoblot (table 3) . Six
Immune response to FHA following vaccination with ACPV. Pre-and postvaccination sera from children who had received other serum samples containing significant levels of anti-FHA antibodies, as determined by ELISA, were obtained from adults three doses of investigational ACPVs were obtained from an NIAID-sponsored phase II study [22] . Two sets of sera from with confirmed pertussis. All 6 of the convalescent serum sam- figure 2C, panel IV) . Both sets of sera elicited by 2 of the vaccines (nos. 3 and 4, 9, and 10) showed very strong tained in the Multicenter Acellular Pertussis Trial [22] . The WCPV used in our study (table 4) elicited a strong type I reactions with FHA and fusion proteins overlapping both major domains, indicating that they contained antibodies that are very response (similar to the results shown in our table 3), in particular a type IA response, and the serum from 1 patient also reactive with both immunodominant regions of FHA. contained antibodies reactive with the type II domains.
The ACPV were composed of combinations of two, three, or Discussion four B. pertussis antigens [22, 29] , including pertussis toxoid, pertactin, and fimbriae types 2 and 3, as well as FHA (table To our knowledge, the studies presented herein describe for the first time two major antigenic domains located within the 4). All sera showed a significant rise in anti-FHA titers after three doses of vaccine, as determined by ELISA. All prevacci-FHA molecule that are recognized by both MAbs and anti-FHA antibodies present in human sera following disease or nation sera had very low anti-FHA titers and were negative by immunoblot (data not shown). By immunoblot analysis (table  vaccination. The dominant type I region, which elicits an immune response in both mice and humans, is located within 4), all postvaccination sera contained antibodies that reacted with the 220-and 150-kDa bands of FHA and, strongly, with Ç450 aa residues of the COOH-terminus of the mature 220-kDa FHA. Most, but not all, of these antibodies strongly inhibit fusion protein Mal85 (see figure 2C for immunoblots for children vaccinated with ACPV), indicating that these sera con-FHA-mediated hemagglutination. Antibodies directed against this region could therefore potentially interfere with some of tained antibodies that recognize the type I region of FHA. Sera from 2 children (nos. 5 and 6) vaccinated with a threethe adhesive activities assigned to FHA [6, 19, 30 -32] and may be important protective antibodies. component ACPV contained antibodies that recognize the type I domain only (table 4) .
We have previously shown that hemagglutination [8] and binding to epithelial cells [19] can be inhibited by sulfated Incorporating the results using fusion protein GR10, 6 of the sera (nos. 1, 2, 6, 9, 10, and 11) from children immunized with glycoconjugates, such as heparin, and that the major heparinbinding site is located in the NH 2 -terminal domain of FHA ACPV could be classified as containing anti-FHA antibodies that predominantly recognize the type IA domain ( figure 2C between residues 441 and 861 [9] . However, our results have also demonstrated that the COOH-terminal half of FHA masks panel II). Three of the sera (nos. 3, 4, and 12) contained antibodies that avidly recognize the type IB region of FHA, althe epitopes of the NH 2 -terminal half of the molecule [20] , Table 4 . FHA reactivity of sera from acellular pertussis vaccine (ACPV) and whole cell pertussis vaccine (WCPV) recipients. [28] . Therefore, it is likely that the observed inhibitory effect of FHA-mediated hemagglutination by type I MAbs is interest, this consensus sequence is also found in a more degenerated form in the A repeats [1] , located further upstream bea result of the hairpin structure of FHA, which would place the COOH-terminal type I domain in close proximity to the tween residues 382 and 664. This may also explain why the type IIB antibodies strongly recognize Fha412, which extends NH 2 -terminal heparin-binding domain.
Another immunodominant region of FHA, the type II dofrom the NH 2 -terminal of FHA to residue 441. In particular, this region contains the sequence VSGRQAV, located within main, is located in the NH 2 -terminal region of FHA and is within the 98-kDa fragment. Antibodies directed against this the first of the A repeats, which is similar to the consensus sequence that defines the type IIB domain. region may also affect B. pertussis adherence, since a MAb directed against the type IIB region inhibits B. pertussis attachAntibodies directed against the type IIC region react with the recombinant fusion proteins Mal83 and GR7 but not with ment to epithelial cells and partially blocks hemagglutination [21] . The region containing the RGD sequence, an attachment Mal80, Fha44, or Fha412. However, pepscan results were equivocal, suggestive of conformational epitopes. Lack of reacsite on FHA that interacts with the CR3 integrin on macrophages [32, 33] , does not appear to elicit a dominant immune tivity with the 150-kDa FHA fragment and with Mal80 assigns this domain to the area found between aa 861 and 1073. response.
Both the type I and type II domains can be subdivided into Studies using sera from vaccinated children and from patients convalescing from pertussis demonstrate that natural regions that contain either linear antibody epitopes (based on immunoblot and pepscan analysis), such as types IA and IIB, infection or immunization of humans with pertussis vaccines induces antibodies directed against FHA domains similar to or epitopes that appear to be more conformational. Antibodies were classified into immunodominant domains by their immuthose recognized by the MAbs. Although the number of sera tested in this investigation are somewhat limited due noblot reactivity with the major fragments of mature FHA and by reactivity with recombinant FHA fragments either produced to difficulties in obtaining human sera, several preliminary conclusions can be drawn. Both disease and vaccination apin E. coli or in B. pertussis.
Type I antibodies reacted specifically with the 150-kDa fragpear to elicit a B cell response to the type I domain. Sera from convalescent patients and from children following adment of FHA, distinguishing them from those that react with the more NH 2 -terminal region of FHA. The type IA domain ministration of WCPV showed mainly a type I response. In contrast, a type II response and a type I response were elicwas defined by antibody reactivity with recombinant proteins Mal85 and GR7 but not with GR10, which indicates that this ited in children vaccinated with ACPV, with the exception of 1 child who received acellular vaccine. In addition, the epitope is located between aa residues 1655 and 2013. Pepscan analysis indicated that at least some of the type IA antibodies sera from children vaccinated with ACPV demonstrated a much stronger reaction overall on immunoblots. This likely recognize a linear epitope within the aa sequence RGHTLE-SAEGRKIFG. The type IB domain was defined by reactivity reflects relatively greater amounts of FHA antigen present in ACPV than in WCPV preparations. Relatively lower antiof the MAb with the recombinant proteins Mal85, GR7, and GR10, which locates it at the very end of the COOH-terminus FHA titers in convalescent sera and in sera from WCPVs also may account for our inability to distinguish between of the mature 220-kDa form of FHA. Lack of specific activity using pepscan analysis suggests that this epitope is conformatype IA and type IB in these groups. Interpretation of the results obtained using the sera from the tional. It is difficult to precisely define the 3 end of the type IB domain since, at present, it is not known exactly where phase II trial, which compared various innovative pertussis vaccines [22] , is complicated because of differences in quanticleavage occurs to produce mature FHA. On the basis of sequence predictions, it is most likely that COOH-terminal cleavties of FHA per vaccine dose; differences in the detoxification and cross-linking of vaccine components, using chemicals or age occurs within either aa GKRG (2150 -2153), EKRL (2218 -2220), or GRRN (2297 -2300). recombinant techniques; and the presence of other pertussis proteins, which might affect immunogenicity. However, as with Type II antibodies specifically recognize the 98-kDa fragment of FHA, assigning them to the region upstream of the convalescent and WCPV sera, 100% of the sera from children immunized with ACPVs contained antibodies that avidly rec-RRARR cleavage site and within the NH 2 -terminal fragment of FHA. The type IIA domain is defined by its reactivity in ognize the type I region, which suggests that this is a major antibody-binding region within FHA. Of these type I reactors, immunoblots with recombinant Mal2, Fha44, and Fha412. The type IIB domain is also defined by reactivity with Mal80, 50% were further categorized as type IA only. Sera from children vaccinated with one three-component vaccine were reacMal83, GR7, Fha44, and Fha412. Pepscan analysis further defined the type IIB epitope as a linear consensus sequence, tive only with the type I region, which is likely due to this vaccine having a relatively low amount of FHA compared VsGrDAVRvd, which occurs both in Mal80 and Mal83, perhaps explaining why these nonoverlapping fusion proteins are with the other acellular vaccines. This vaccine also induced a relatively lower total antibody response to FHA compared with both reactive in immunoblots. This sequence is part of the (see table 3 in [22] ). Using the methods described not known which antigenic domains of FHA confer protection, it would be especially valuable to investigate the immune rehere, it cannot be determined whether the remaining type I sera contain antibodies directed against both type IA and type IB.
sponses to more defined areas within the extensive FHA molecule. This could be accomplished using appropriate sera obThe type II region is also recognized by antibodies in Ç80% of the sera from children vaccinated with ACPV. Reactivity tained from clinical trials and certain of the recombinant protein constructs encoding major immunodominant domains in immuof the sera with the recombinant proteins indicated that many of the type II reactors may recognize both subtypes located in nologic assays as described in this report. These recombinant constructs should also be useful for further defining the functhis region.
Taken together, these results indicate that the COOH-termitional adhesive sites found on FHA and for attempting to correlate functional sites with protective antibodies in animal sysnal region of mature FHA, defined by the type I domain, is the most immunodominant part of the molecule for both mice tems and in human clinical trials. and humans. Most MAbs recognize this region, as do all the sera from either convalescent patients or subjects who received
